The CEO of MergerTech Nitin Khanna was born in India in 1971. He holds both undergraduate and graduates degrees in Industrial Engineering. Nitin Khanna is recognized for his various investments, as a successful entrepreneur and a leader who has helped various companies to succeed. As he was growing up, he spent lots of time in businesses such as motorcycle parts factory and cement plants when he acquired some insight on how to lead his own enterprise in the future.
Nitin Khanna founded his first company Saber Software in collaboration with his brother in 1999 and for the decade that followed, they concentrated on growing the business. The company was contracted by the government in 2001 to use its software in managing the voting process. The company continued to gain more success and by the time Nitin Khanna and his partner were selling it to EDS in 2008, it had 1,500 employees with annual revenue of $300 million.
It is after the sale that he embarked on investing in about 50 companies in Portland. His interested was to see as many companies as possible to succeed in this region. Nitin Khanna had gained lots of experience about mergers from the sale of Saber Software and so in 2009, he decided to open MergerTech as a mergers and acquisitions advisory firm whose target market was the technology companies that needed to maximize their outcome by identifying the most ideal strategic partners.
Nitin Khanna is an entrepreneur who has always ensured to be a step ahead of the competition. When the market for legal cannabis exploded in 2012, he was one of the early investors. By 2015, Cura Cannabis entered this market and its board sought Nitin Khanna for his expertise to lead the company as the Chief Executive Officer. Currently, it has become the largest cannabis company in the world selling edibles and oils.
Nitin Khanna is an individual that does not believe in maintaining a work-life balance. His perception is that when one is doing what they love, it becomes an extension of who they are. According to Nitin Khanna, success does not come with finding the balance between the two but finding a way to integrate both.
Find out more here https://medium.com/@bankingonit/a-progressive-future-for-cannabis-why-nitin-khanna-supports-portland-based-accelerator-the-9ad4b0ae624
Renovia Inc. recently raised $42 million toward the establishment of a new pipeline of drugs as well as therapeutic products made to target pelvic floor disorders that affect more than 200 million women across the world. Situated in Boston, the revolutionary medtech company is seeking the support of various donors when it comes to treating disorders including urinary incontinence. In the fundraiser, $10 million was raised and channelled toward the project. $32 million was raised from a round of Series B Funding that was chaired by Perceptive Advisors alongside Ascension Ventures. The two firms are situated in New York as well as Missouri in that order. Longwood Fund was part of the project as well.
Regarding the contribution, Marc Beer, CEO of Renovia Inc stated that he was elated by this investor’s support. He added that the donation would be forwarded toward the development of drugs that would occur through the combination of the company’s proprietary form factors as well as sensor technologies. In the long-run, the idea would offer constructive data-driven treatment dockets aimed at cutting down the healthcare costs for treating pelvic floor disorders.
Renovia Inc. created Leva for pelvic floor strengthening customized to help individuals suffering from different forms of pelvic floor disorders. The healthcare system has sensor technology that is designed to allow the user to identify the position of the pelvic floor muscles during exercise. The FDA has approved the device. It has also been cleared for training patient’s weak pelvic floor muscles particularly when treating stress incontinence in addition to the moderate urge incontinence.
Marc Beer established Renovia Inc. in 2016. He is the chairman of the company and has been serving in the sector of biotechnology for over two decades. Beer is prominent for working with various companies in the same industry. They include ViaCell in which he served as the CEO and founding partner. With his guidance, the company specialized in developing as well as preserving stem cells harvested from the umbilical cord. In 2007, Beer served at PerkinElmer before acquiring it.
Additionally, he worked at Erytech Pharma which is a biopharmaceutical firm. Marc Beer also served as a member of the board of directors. Moreover, Marc Beer has worked at Genzyme where he was the VP of Global Marketing. He assisted the company to launch various brands made for treating rare diseases in the world.
Renovia Inc. was established to create and commercialize products for better diagnosis as well as treatment to improve the conditions of millions of women who suffer from pelvic floor disorders. The technology makes it possible for patients to gain access to treatment through accurate visualization of various pelvic floor movements during training. The process is also monitored to establish the results. Learn more: https://renoviainc.com/leadership/